Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2018 (2018), Article ID 3967213, 16 pages
https://doi.org/10.1155/2018/3967213
Research Article

Effect of the Antioxidant Lipoic Acid in Aortic Phenotype in a Marfan Syndrome Mouse Model

1Vascular Biology Laboratory, Heart Institute (InCor), School of Medicine, University of São Paulo, São Paulo, SP, Brazil
2Laboratory of Metabolism and Lipids, Heart Institute (InCor), School of Medicine, University of São Paulo, São Paulo, SP, Brazil
3Heart Failure Unit, Heart Institute (InCor), School of Medicine, University of São Paulo, São Paulo, SP, Brazil
4Department of Interventional Cardiology, Heart Institute (InCor), School of Medicine, University of São Paulo, São Paulo, SP, Brazil
5National Laboratory for Embryonic Stem Cells (LaNCE), Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of São Paulo, São Paulo, SP, Brazil

Correspondence should be addressed to Maria C. Guido; rb.psu.rocni@odiugloracm

Received 6 October 2017; Accepted 24 January 2018; Published 25 March 2018

Academic Editor: Janusz Gebicki

Copyright © 2018 Maria C. Guido et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. P. Judge and H. C. Dietz, “Therapy of Marfan syndrome,” Annual Review of Medicine, vol. 59, no. 1, pp. 43–59, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. N. M. Ammash, T. M. Sundt, and H. M. Connolly, “Marfan syndrome—diagnosis and management,” Current Problems in Cardiology, vol. 33, no. 1, pp. 7–39, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. P. M. Engelfriet, E. Boersma, J. G. Tijssen, B. J. Bouma, and B. J. Mulder, “Beyond the root: dilatation of the distal aorta in Marfan’s syndrome,” Heart, vol. 92, no. 9, pp. 1238–1243, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. F. S. Schoenhoff, S. Jungi, M. Czerny et al., “Acute aortic dissection determines the fate of initially untreated aortic segments in Marfan syndrome,” Circulation, vol. 127, no. 15, pp. 1569–1575, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. C. D. van Karnebeek, M. S. Naeff, B. J. Mulder, R. C. Hennekam, and M. Offringa, “Natural history of cardiovascular manifestations in Marfan syndrome,” Archives of Disease in Childhood, vol. 84, no. 2, pp. 129–137, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Pereira, S. Y. Lee, B. Gayraud et al., “Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 7, pp. 3819–3823, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. K. M. Summers, M. Nataatmadja, D. Xu et al., “Histopathology and fibrillin-1 distribution in severe early onset Marfan syndrome,” American Journal of Medical Genetics Part A, vol. 139A, no. 1, pp. 2–8, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Wu, Y. H. Shen, L. Russell, J. S. Coselli, and S. A. LeMaire, “Molecular mechanisms of thoracic aortic dissection,” The Journal of Surgical Research, vol. 184, no. 2, pp. 907–924, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. J. P. Habashi, D. P. Judge, T. M. Holm et al., “Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome,” Science, vol. 312, no. 5770, pp. 117–121, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. J. H. Lindeman, B. A. Ashcroft, J. W. Beenakker et al., “Distinct defects in collagen microarchitecture underlie vessel-wall failure in advanced abdominal aneurysms and aneurysms in Marfan syndrome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 2, pp. 862–865, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Radonic, P. de Witte, M. Groenink et al., “Inflammation aggravates disease severity in Marfan syndrome patients,” PLoS One, vol. 7, no. 3, article e32963, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Collod-Béroud, S. Le Bourdelles, L. Ades et al., “Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database,” Human Mutation, vol. 22, no. 3, pp. 199–208, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. J. R. Cook, L. Carta, J. Galatioto, and F. Ramirez, “Cardiovascular manifestations in Marfan syndrome and related diseases; multiple genes causing similar phenotypes,” Clinical Genetics, vol. 87, no. 1, pp. 11–20, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. B. L. Lima, E. J. Santos, G. R. Fernandes et al., “A new mouse model for marfan syndrome presents phenotypic variability associated with the genetic background and overall levels of Fbn1 expression,” PLoS One, vol. 5, no. 11, article e14136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. B. L. Loeys, “Angiotensin receptor blockers: a panacea for Marfan syndrome and related disorders?” Drug Discovery Today, vol. 20, no. 2, pp. 262–266, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. T. M. Holm, J. P. Habashi, J. J. Doyle et al., “Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice,” Science, vol. 332, no. 6027, pp. 358–361, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. J. P. Habashi, J. J. Doyle, T. M. Holm et al., “Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism,” Science, vol. 332, no. 6027, pp. 361–365, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Groenink, A. W. den Hartog, R. Franken et al., “Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial,” European Heart Journal, vol. 34, no. 45, pp. 3491–3500, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. R. V. Lacro, H. C. Dietz, L. A. Sleeper et al., “Atenolol versus losartan in children and young adults with Marfan’s syndrome,” The New England Journal of Medicine, vol. 371, no. 22, pp. 2061–2071, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. C. C. Winterbourn, “Reconciling the chemistry and biology of reactive oxygen species,” Nature Chemical Biology, vol. 4, no. 5, pp. 278–286, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Buday, P. Orsy, M. Godó et al., “Elevated systemic TGF-β impairs aortic vasomotor function through activation of NADPH oxidase-driven superoxide production and leads to hypertension, myocardial remodeling, and increased plaque formation in apoE−/− mice,” American Journal of Physiology. Heart and Circulatory Physiology, vol. 299, no. 2, pp. H386–H395, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Samarakoon, J. M. Overstreet, and P. J. Higgins, “TGF-β signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities,” Cellular Signalling, vol. 25, no. 1, pp. 264–268, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Nguyen Dinh Cat, A. C. Montezano, D. Burger, and R. M. Touyz, “Angiotensin II, NADPH oxidase, and redox signaling in the vasculature,” Antioxidants & Redox Signaling, vol. 19, no. 10, pp. 1110–1120, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. H. L. Matlung, E. N. Bakker, and E. VanBavel, “Shear stress, reactive oxygen species, and arterial structure and function,” Antioxidants & Redox Signaling, vol. 11, no. 7, pp. 1699–1709, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. K. G. Birukov, “Cyclic stretch, reactive oxygen species, and vascular remodeling,” Antioxidants & Redox Signaling, vol. 11, no. 7, pp. 1651–1667, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. W. Xiong, T. Meisinger, R. Knispel, J. M. Worth, and B. T. Baxter, “MMP-2 regulates Erk1/2 phosphorylation and aortic dilatation in Marfan syndrome,” Circulation Research, vol. 110, no. 12, pp. e92–e101, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Fiorillo, M. Becatti, M. Attanasio et al., “Evidence for oxidative stress in plasma of patients with Marfan syndrome,” International Journal of Cardiology, vol. 145, no. 3, pp. 544–546, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. H. H. Yang, C. van Breemen, and A. W. Chung, “Vasomotor dysfunction in the thoracic aorta of Marfan syndrome is associated with accumulation of oxidative stress,” Vascular Pharmacology, vol. 52, no. 1-2, pp. 37–45, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. H. H. Yang, J. M. Kim, E. Chum, C. van Breemen, and A. W. Chung, “Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome,” The Journal of Thoracic and Cardiovascular Surgery, vol. 140, no. 2, pp. 305–312.e2, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Costa, M. Garabito, F. Jiménez-Altayó et al., “Sex differences in angiotensin II responses contribute to a differential regulation of cox-mediated vascular dysfunction during aging,” Experimental Gerontology, vol. 85, pp. 71–80, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. H. H. Yang, J. M. Kim, E. Chum, C. van Breemen, and A. W. Chung, “Long-term effects of losartan on structure and function of the thoracic aorta in a mouse model of Marfan syndrome,” British Journal of Pharmacology, vol. 158, no. 6, pp. 1503–1512, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. R. A. Sirvente, M. C. Irigoyen, L. E. Souza et al., “Cardiac impairment evaluated by transesophageal echocardiography and invasive measurements in rats undergoing sinoaortic denervation,” PLoS One, vol. 9, no. 5, article e87935, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. V. M. Salemi, A. M. Bilate, F. J. Ramires et al., “Reference values from M-mode and Doppler echocardiography for normal Syrian hamsters,” European Journal of Echocardiography, vol. 6, no. 1, pp. 41–46, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Bassi, M. Liberman, M. K. Martinatti, L. A. Bortolotto, and F. R. Laurindo, “Lipoic acid, but not tempol, preserves vascular compliance and decreases medial calcification in a model of elastocalcinosis,” Brazilian Journal of Medical and Biological Research, vol. 47, no. 2, pp. 119–127, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. B. S. Brooke, J. P. Habashi, D. P. Judge, N. Patel, B. Loeys, and H. C. Dietz 3rd, “Angiotensin II blockade and aortic-root dilation in Marfan’s syndrome,” The New England Journal of Medicine, vol. 358, no. 26, pp. 2787–2795, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. F. Ramirez and H. C. Dietz, “Extracellular microfibrils in vertebrate development and disease processes,” The Journal of Biological Chemistry, vol. 284, no. 22, pp. 14677–14681, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Ramirez and H. C. Dietz, “Marfan syndrome: from molecular pathogenesis to clinical treatment,” Current Opinion in Genetics & Development, vol. 17, no. 3, pp. 252–258, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. W. Xiong, R. A. Knispel, H. C. Dietz, F. Ramirez, and B. T. Baxter, “Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome,” Journal of Vascular Surgery, vol. 47, no. 1, pp. 166–172, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. A. W. Chung, H. H. Yang, M. W. Radomski, and C. van Breemen, “Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9,” Circulation Research, vol. 102, no. 8, pp. e73–e85, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Goraca, H. Huk-Kolega, A. Piechota, P. Kleniewska, E. Ciejka, and B. Skibska, “Lipoic acid—biological activity and therapeutic potential,” Pharmacological Reports, vol. 63, no. 4, pp. 849–858, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Petersen Shay, R. F. Moreau, E. J. Smith, and T. M. Hagen, “Is α-lipoic acid a scavenger of reactive oxygen species in vivo? Evidence for its initiation of stress signaling pathways that promote endogenous antioxidant capacity,” IUBMB Life, vol. 60, no. 6, pp. 362–367, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. D. Tibullo, G. Li Volti, C. Giallongo et al., “Biochemical and clinical relevance of alpha lipoic acid: antioxidant and anti-inflammatory activity, molecular pathways and therapeutic potential,” Inflammation Research, vol. 66, no. 11, pp. 947–959, 2017. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Carta, S. Smaldone, L. Zilberberg et al., “p38 MAPK is an early determinant of promiscuous Smad2/3 signaling in the aortas of fibrillin-1 (Fbn1)-null mice,” The Journal of Biological Chemistry, vol. 284, no. 9, pp. 5630–5636, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Hibender, R. Franken, C. van Roomen et al., “Resveratrol inhibits aortic root dilatation in the Fbn1C1039G/+ Marfan mouse model,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 36, no. 8, pp. 1618–1626, 2016. View at Publisher · View at Google Scholar · View at Scopus